Linagliptin Eg (Eurogenerics) Nv

Linagliptin, the active ingredient in Linagliptin Eg (Eurogenerics) Nv, is a DPP‑4 inhibitor presented as a tablet for oral use. It helps control blood glucose in adults with type 2 diabetes mellitus.

GNH USA supplies Linagliptin Eg (Eurogenerics) Nv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus, either alone or with other antidiabetic agents. - Type 2 diabetes mellitus (monotherapy): improves glycaemic control by enhancing insulin secretion and reducing glucagon release. - Type 2 diabetes mellitus (combination therapy): used together with metformin, sulfonylureas or insulin to achieve target HbA1c levels. - Type 2 diabetes mellitus (renal impairment): provides effective glucose lowering without dose adjustment in mild to moderate renal dysfunction.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea. - Back pain: non‑specific musculoskeletal pain. - Skin rash: mild erythematous rash.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: angio‑edema, urticaria, anaphylaxis. - Hepatic injury: jaundice, elevated liver enzymes. - Hypoglycaemia (when combined with insulin or sulfonylureas): symptomatic low blood glucose. - Bullous pemphigoid: rare autoimmune skin blistering disorder.

Linagliptin should be used with clinical vigilance in the following situations: - Renal impairment: monitor renal function; dose adjustment may be required in severe cases. - Hepatic impairment: assess liver enzymes regularly. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Pregnancy: safety not established; prescribe only if potential benefit justifies risk. - Elderly patients: monitor for increased adverse events due to polypharmacy. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with several medicines; awareness of the interaction level helps guide monitoring. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce linagliptin effectiveness. Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose if needed. - Diuretics: monitor volume status and electrolytes. - ACE inhibitors or ARBs: watch blood pressure and renal function.